Jenner & Block

 

REPRESENTATIVE MATTERS

  • Snyder’s-Lance Inc. in its $6.1 billion sale to Campbell Soup Company;
  • Swiss-based Lonza Group Ltd. in its acquisition of all outstanding shares of Capsugel SA, for a purchase price of $5.5 billion;
  • Swiss-based Lonza Group Ltd. in a $2.3 billion rights offering and in an $865 million accelerated bookbuilding offering;
  • US Foods Holding Corp. (NYSE: USFD) in its $1.175 billion initial public offering;
  • US Foods Holding Corp (NYSE: USFD) in a $1 billion secondary offering of common stock;
  • Snyder’s-Lance Inc. in its $1.8 billion acquisition of Diamond Foods Inc. (Nasdaq:DMND);
  • Clementia Pharmaceuticals (Nasdaq: CMTA) in its $137.9 million initial public offering;
  • NPS Pharmaceuticals in its $100 million public offering of common stock;
  • US Foods in its registered $1.35 billion debt exchange offer;
  • Clementia Pharmaceuticals in its $60 million cross-over private placement;
  • Swiss-based Lonza Group Ltd. in its agreement to acquire all of the outstanding shares of Arch Chemicals, Inc., for a purchase price of approximately $1.2 billion;
  • Bayer HealthCare AG in its collaboration agreement with Nuvelo for alfimeprase and its collaboration agreement with ZymoGenetics;
  • Bayer HealthCare LLC in its license and collaboration agreement with Regeneron Pharmaceuticals for VEGF Trap;
  • Tengion, Inc., a leader in the field of regenerative medicine, in its initial public offering and its Series C financing;
  • Obagi Medical Products, Inc., in its initial public offering and its $144.9 million follow-on public offering;
  • Heartland Payment Systems, Inc., a credit card payment processor, in its initial public offering and its $145 million follow-on public offering;
  • Otsuka Pharmaceutical in its $200 million acquisition of the Busulfex assets from PDL BioPharma and its acquisition of Interpharma Praha, a.s., a Czech Republic-based pharmaceutical manufacturer;
  • Enzon Pharmaceuticals in its sale of a portion of its royalty interest for PEG- Intron;
  • A.L. Industrier AS, the controlling shareholder of Alpharma, Inc., in its sale of its interest in Alpharma for $305 million.